Acupuncture and Moxibustion Enter the Prediabetes Conversation
Prediabetes sits in a difficult middle ground: not yet type 2 diabetes, yet far from metabolically benign. In this 2026 review in International Journal of General Medicine, Niu, Zhang, Deng, Wu, and Wang frame the condition as a silent global epidemic marked by rising prevalence and substantial cardiometabolic risk. The article also confronts a problem that complicates both research and bedside care: the diagnostic criteria are established, but real-world screening remains messy, with persistent disagreements over definitions, inter-ethnic variation, and poor concordance across fasting glucose, HbA1c, and postprandial glucose testing.
Prediabetes is not a single biological state. It reflects overlapping disturbances in glucose regulation that can differ by phenotype and by organ system, which helps explain why one person may first show impaired fasting glucose while another presents with impaired glucose tolerance. Hepatic insulin resistance dominates in one pattern, skeletal muscle insulin resistance in another, and both sit beside progressive β-cell dysfunction. The review places chronic low-grade inflammation, mitochondrial dysregulation, and lipotoxicity at the center of this process, creating a pathophysiologic rationale for treatments that influence more than one pathway at once.
Metabolic Dysfunction Spans Several Organs at Once
The clinical logic of prediabetes is broader than blood sugar alone. Insulin resistance in the liver raises fasting glucose, while impaired handling of postprandial glucose often reflects skeletal muscle dysfunction and worsening β-cell reserve. A therapy that only lowers glucose transiently may miss the deeper problem if it does not also affect endocrine signaling, inflammation, or neurohumoral stress responses.
This is where the article places acupuncture and moxibustion. Rooted in traditional Chinese medicine, the interventions are presented here not as symbolic remedies but as multimodal approaches increasingly examined through modern mechanistic work. The review argues that their appeal lies in their capacity to act across several intersecting systems rather than on a single biochemical target.
Clinical Evidence Points to Glucose and Insulin Benefits
Across randomized controlled trials and meta-analyses, acupuncture-related therapies have been associated with reductions in fasting blood glucose, postprandial glucose, and HbA1c. The review also describes improvements in insulin resistance, which is clinically meaningful because insulin resistance often precedes overt diabetes by years and drives much of the metabolic burden in prediabetes.
A key strength of the article is that it does not reduce the discussion to glycemic numbers alone. It links the observed metabolic effects to biologically plausible mechanisms, including modulation of the leptin signaling pathway and restoration of β-cell homeostasis. In practical terms, those pathways matter because leptin signaling interacts with energy balance and glucose regulation, while β-cell preservation may slow the slide from dysglycemia into established diabetes.
One sentence in the review carries more weight than any single endpoint table could: the therapeutic interest is not limited to glucose lowering, but to the possibility of influencing the underlying regulatory network that drives progression.
Neuroendocrine Pathways Offer a Plausible Mechanism
The review devotes substantial attention to neuroendocrine regulation, including the vago-islet axis and the hypothalamic-pituitary-adrenal axis. That focus is clinically important because metabolic disease is never purely pancreatic or hepatic; it is also shaped by autonomic tone, stress physiology, and central control of peripheral metabolism.
If acupuncture and related therapies can alter those signaling pathways, even partially, the effect could extend beyond laboratory glucose values. Reduced sympathetic overdrive, improved vagal signaling, and dampened stress-axis activation would all be compatible with better insulin sensitivity and more stable β-cell function. The review does not claim that these mechanisms have been definitively proven in large human datasets, but it presents them as a coherent framework supported by emerging experimental and clinical observations.
Newer Protocols Expand the Therapeutic Vocabulary
The manuscript also reviews several innovative approaches, including electroacupuncture, Zhuang medicine scraping combined with blood-letting, and auricular acupoint embedding. Each is presented as part of a broader effort to refine traditional techniques into reproducible clinical protocols with measurable metabolic effects.
Safety receives attention as well. The review characterizes these approaches as having favorable safety profiles, which is especially relevant in prediabetes, where interventions are often intended for prevention rather than rescue. A low-risk intervention has a different clinical threshold than an aggressive treatment for advanced disease. When the population includes people who are not yet diabetic, tolerability and scalability become central considerations.
Methodologic Limits Still Shape the Evidence Base
The current evidence is encouraging, but the review is explicit about its constraints. Methodologic heterogeneity remains a major obstacle, and the studies summarized are limited by small sample sizes and scarce long-term follow-up. Those limitations make it difficult to determine how durable the metabolic effects are, which protocols are most effective, and whether benefits translate into fewer cases of type 2 diabetes over time.
Standardization is another unresolved issue. Acupuncture and moxibustion studies often vary in point selection, frequency, treatment duration, and comparator design. Without harmonized protocols, pooling results becomes more difficult and clinical interpretation less certain. The result is a field with promising signals but uneven reproducibility.
A Research Agenda Built Around Standardization and Mechanism
The article ends by calling for large-scale multicenter trials, multi-omics mechanistic studies, and standardized clinical protocols. That agenda is clinically sensible because prediabetes is too heterogeneous for one-size-fits-all treatment claims. A larger, more rigorous evidence base would need to determine whether observed metabolic benefits persist across populations, whether they differ by phenotype, and which biological pathways best explain the response.
For now, the review positions acupuncture and moxibustion as scientifically grounded interventions with potential preventive value, not as replacements for established metabolic care. Their place in prediabetes will depend on whether future trials can move beyond short-term glucose changes and demonstrate durable effects on progression, biology, and patient-centered outcomes. The unanswered question is not whether the field has generated hypotheses, but whether those hypotheses can survive larger trials with longer follow-up and consistent methods.